A Decades-Long Alliance: Syngene and Bristol Myers Squibb Extend R&D Partnership to 2035

In a major move for the global biopharmaceutical sector, Syngene International and Bristol Myers Squibb (BMS) have announced an extension of their strategic collaboration through 2035. This ten-year renewal solidifies a relationship that has spanned over 25 years, focusing on accelerating the journey of life-saving medicines from the laboratory to the patient.

Expanding the Drug Development Lifecycle

The new agreement significantly broadens the scale of services Syngene provides. Rather than focusing on isolated stages, the partnership now integrates services across the entire drug development pipeline:

Early Discovery: High-end chemistry, biology, and drug metabolism/pharmacokinetics (DMPK).
Translational Sciences: Bridging the gap between laboratory research and clinical applications.
Development & Manufacturing: Scaling up chemical processes and manufacturing clinical trial materials.
Clinical & Data Support: Providing the IT infrastructure and data analytics necessary for modern clinical trials.

The Power of the BBRC

Central to this partnership is the Biocon Bristol Myers Squibb Research and Development Center (BBRC). Established in 2009, this dedicated facility has become a cornerstone of BMS’s global research strategy.

Key Statistics of the BBRC:

Workforce: Approximately 700 Syngene scientists dedicated exclusively to BMS projects.
Therapeutic Focus: Critical research in Oncology, Immunology, Fibrosis, and Cardiovascular Disease.
Efficiency: The center is credited with significantly reducing the timelines and costs associated with moving novel compounds through preclinical milestones.

Strategic Significance: Stability in Innovation

The decision to extend the contract for a full decade—rather than a standard 3 or 5-year term—is a calculated strategic move.

Feature	Strategic Benefit
Long-Term Horizon	Allows for massive investment in specialized infrastructure and bespoke technologies.
Operational Synergy	25+ years of shared history reduces “friction” in communication and data sharing.
Integrated Model	Moving from a “service provider” to an “extension of the team” model improves R&D speed.

“The decade-long horizon will allow both companies to build new capabilities and infrastructure with strategic foresight.” — Peter Bains, CEO of Syngene International

Looking Toward 2035

By securing this partnership until 2035, Syngene reinforces its position as a top-tier CRDMO (Contract Research, Development, and Manufacturing Organization). For BMS, the extension ensures a stable, high-quality research engine in India that can support its ambitious global pipeline of transformative medicines.